Waltham Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Waltham
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Waltham News
Progressives take on Democratic incumbents as midterm primaries kick off
Allam has the support of progressive stalwart independent Sen. Bernie Sanders, who campaigned for her in mid-February and told supporters at a rally, "At a moment when the oligarchs are tightening ...
If You're Retired, You Might Want To Consider Getting Identity Theft Insurance. Here's Why.
Car insurance, health insurance, homeowners insurance — there are plenty of protections people prioritize to save money and headaches in case of an incident. But for retirees, experts say there’s ...
Dianthus Therapeutics, Inc. Announces Closing of its Upsized 9 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing ...
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
Report Highlights the Company's Collaboration with GARDP to Develop NUZOLVENCE (R) (zoliflodacin) for Oral Suspension for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Pediatric ...